➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Express Scripts
Harvard Business School
Moodys
AstraZeneca
Baxter

Last Updated: September 27, 2021

DrugPatentWatch Database Preview

camcevi kit Drug Patent Profile


Email this page to a colleague

« Back to Dashboard

Which patents cover Camcevi Kit, and when can generic versions of Camcevi Kit launch?

Camcevi Kit is a drug marketed by Foresee Pharms and is included in one NDA. There are three patents protecting this drug.

This drug has twenty patent family members in fifteen countries.

The generic ingredient in CAMCEVI KIT is leuprolide mesylate. There are twenty-two drug master file entries for this compound. Additional details are available on the leuprolide mesylate profile page.

DrugPatentWatch® Generic Entry Outlook for Camcevi Kit

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be January 16, 2027. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Try it Free

Summary for camcevi kit
International Patents:20
US Patents:3
Applicants:1
NDAs:1
DailyMed Link:camcevi kit at DailyMed
Drug patent expirations by year for camcevi kit
DrugPatentWatch® Estimated Generic Entry Opportunity Date for camcevi kit
Generic Entry Date for camcevi kit*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
EMULSION;SUBCUTANEOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for camcevi kit

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Foresee Pharms CAMCEVI KIT leuprolide mesylate EMULSION;SUBCUTANEOUS 211488-001 May 25, 2021 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
Foresee Pharms CAMCEVI KIT leuprolide mesylate EMULSION;SUBCUTANEOUS 211488-001 May 25, 2021 RX Yes Yes ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Foresee Pharms CAMCEVI KIT leuprolide mesylate EMULSION;SUBCUTANEOUS 211488-001 May 25, 2021 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
Foresee Pharms CAMCEVI KIT leuprolide mesylate EMULSION;SUBCUTANEOUS 211488-001 May 25, 2021 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Express Scripts
Harvard Business School
Moodys
AstraZeneca
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.